Formation of the IGF:IGFBP5:ALS complex

Stable Identifier
R-HSA-381545
Type
Reaction [binding]
Species
Homo sapiens
Compartment
ReviewStatus
5/5
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
IGFBP 5 binds IGF I or IGF II via the conserved N terminus and C terminus of IGFBP 5. IGFBP 5 also binds ALS via the central portion of IGFBP 5. About 55% of IGF:IGFBP 5 complexes contain ALS. IGFBP 5 is enriched in bone matrix and acts to stimulate IGF function. IGFBP 5 is cleaved by Pregnancy associated Plasma Protein A2 (PAPP A2), ADAM 9, complement C1s from smooth muscle, and thrombin. Only the cleavage site for PAPP A2 is known. About 55% of IGF:IGFBP 5 complexes contain ALS; 45% contain only IGF and IGFBP 5.
Literature References
PubMed ID Title Journal Year
7683646 Binding of mutants of human insulin-like growth factor II to insulin-like growth factor binding proteins 1-6

Hsieh, S, Sakano, K, Rechler, MM, Fujiwara, H, Bach, LA, Perdue, JF

J Biol Chem 1993
12466191 Cellular actions of the insulin-like growth factor binding proteins

Baxter, RC, Firth, SM

Endocr Rev 2002
17047378 The role of insulin-like growth factor binding proteins

Perks, C, Holly, J

Neuroendocrinology 2006
12379487 IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms

Mohan, S, Baylink, DJ

J Endocrinol 2002
9786878 Insulin-like growth factor-binding protein 5 complexes with the acid-labile subunit. Role of the carboxyl-terminal domain

Kiefer, MC, Zapf, J, Twigg, SM, Baxter, RC

J Biol Chem 1998
9497324 Insulin-like growth factor (IGF)-binding protein 5 forms an alternative ternary complex with IGFs and the acid-labile subunit

Twigg, SM, Baxter, RC

J Biol Chem 1998
15126567 The role of the acid-labile subunit in regulating insulin-like growth factor transport across human umbilical vein endothelial cell monolayers

Payet, LD, Baxter, RC, Firth, SM

J Clin Endocrinol Metab 2004
7689487 Glucose does not influence the insulin-like growth factor (JGF) binding to carrier proteins (IGFBPs): analysis of rat and human serum by western ligand blotting

Savage, MO, Holly, JM, Frost, VJ, Cianfarani, S

Experientia 1993
10614670 A central domain binding site in insulin-like growth factor binding protein-5 for the acid-labile subunit

Kiefer, MC, Zapf, J, Twigg, SM, Baxter, RC

Endocrinology 2000
8781553 Measurement of insulin-like growth factor (IGF)-II binding to purified IGF binding proteins 1-6: comparison of charcoal adsorption and high performance size exclusion chromatography

Rechler, MM, Bach, LA

Biochim Biophys Acta 1996
7519608 Heparin, heparan sulfate, and dermatan sulfate regulate formation of the insulin-like growth factor-I and insulin-like growth factor-binding protein complexes

Arai, T, Busby W, Jr, Parker, A, Clemmons, DR

J Biol Chem 1994
11788658 Molecular distribution of IGF binding protein-5 in human serum

Baxter, RC, Firth, SM, Meka, S

J Clin Endocrinol Metab 2002
11316783 Mutagenesis of basic amino acids in the carboxyl-terminal region of insulin-like growth factor binding protein-5 affects acid-labile subunit binding

Baxter, RC, Clemmons, DR, Firth, SM

Endocrinology 2001
10810289 Binding characteristics of pro-insulin-like growth factor-II from cancer patients: binary and ternary complex formation with IGF binding proteins-1 to -6

Baxter, RC, Meka, S, Bond, JJ

J Endocrinol 2000
Participants
Participates
Orthologous Events
Reviewed
Created
Cite Us!